SNMMI's communications staff is available to handle your inquiries, arrange interviews with experts, provide copies of research articles and more.
For assistance, please contact Laurie Callahan, public relations, at firstname.lastname@example.org or (703) 652-6773.
SNMMI is dedicated to being the premier source of information on nuclear medicine and molecular imaging. SNMMI's online newsroom provides reporters with the information needed to write articles and gain background information on the many topics related to molecular imaging and therapy and nuclear medicine.
SNMMI issues press releases on new research, society updates and industry news for members of the press. Check back frequently to see what's new with SNMMI.
View press releases on the latest research and news from SNMMI.
Nuclear and molecular imaging are vital elements of today's medical practice, adding an additional dimension to diagnosis that can change the way diseases are understood and treated. Nuclear medicine therapies treat specific diseases, such as lymphoma or thyroid cancer, by allowing a high dose of medicine to be delivered directly to a tumor or problem area. SNMMI's fact sheets explain how nuclear medicine and molecular imaging can help diagnose and/or treat a wide range of diseases.
SNMMI publishes two peer-reviewed medical journals—The Journal of Nuclear Medicine (JNM) and The Journal of Nuclear Medicine Technology (JNMT)—which feature the latest in molecular imaging research. JNM and JNMT are the most widely read peer-reviewed publications in molecular imaging, nuclear medicine and allied disciplines.
Every month, JNM brings readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and research. JNM's Newsline offers in-depth reporting on news affecting every facet of the field—the latest scientific events, government decisions, industry developments, socio-economic trends, and a broad selection of reviews from the literature.
Published quarterly, JNMT focuses on technology, quality assurance, radiation safety, and the clinical applications of nuclear medicine. Each issue features continuing education articles written by leading educators in nuclear medicine technology as well as news and updates on practice, licensure, and credentialing for nuclear medicine technologists. Practitioners from across the imaging sciences turn to JNMT for peer-reviewed information related to daily clinical practice.
SNMMI can connect you with subject-matter experts on a variety of topics who are ready to respond to tight deadlines. Contact Laurie Callahan, SNMMI's acting associate director of public relations, at email@example.com or at (703) 652-6773, to set up an interview with SNMMI's leadership or with one of its many experts on oncology, brain disease, heart disease, radiopharmaceuticals, reimbursement and more.
Join SNMMI on our social media networks to stay updated on the latest from the society and the nuclear medicine and molecular imaging field.
SNMMI 2017 Annual Meeting News, Announcements, Research
June 10-14, Denver, Colorado
Colorado Convention Center
Scientific Research - (All releases embargoed until Monday, June 12, 2017, at 12:30 pm MDT; contact Laurie Callahan at firstname.lastname@example.org, 703-652-6773-office, 571-294-1973-cell, if you need embargoed releases in advance)
General Clinical Specialties
Instrumentation and Data Analysis
Molecular Targeting Probes
Oncology - Basic
Oncology - Clinical
Also announced at the Annual Meeting: SNMMI Image of the Year, SNMMI/SNMMI-TS Officers, and Awards
The FDA issued two draft guidances that describe FDA’s proposed policies regarding the compounding and repackaging of radiopharmaceuticals for human use by state-licensed nuclear pharmacies or federal facilities, and outsourcing facilities.
(Government Relations News)
In an article published in the January 2017 issue of "The Journal of Nuclear Medicine," researchers assert that exposure to medical radiation does not increase a person’s risk of getting cancer.
A new therapeutic agent for radioligand therapy called lutetium-177-labeled PSMA-617 is showing promise in a German multi-center study for treating patients with metastatic castration-resistant prostate cancer. The research was recently published in "The Journal of Nuclear Medicine."
(SNMMI in the News)
In an article published in the January 2017 issue of "The Journal of Nuclear Medicine," researchers assert that exposure to medical radiation does not increase a person's risk of getting cancer. The long-held belief that even low doses of radiation, such as those received in diagnostic imaging, increase cancer risk is based on an inaccurate, 70-year-old hypothesis, according to the authors.
(SNMMI in the News)
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the National Cancer Institute (NCI) held a joint workshop—NCI-SNMMI Workshop on Targeted Radionuclide Therapy—on October 24-25, 2014, at the National Institutes of Health (NIH) in Bethesda, Md.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis.